Pharmaceuticals
Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
CAESAREA, Israel, Jan. 16, 2024 /PRNewswire/ -- Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety and efficacy of Epitomee® capsule versus the sham capsule ...
2024-01-16 21:00
1444
Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab
A meeting was also held in Germany to announce the results of the international pharmacokinetic similarity clinical (Phase 1) study BERLIN, Jan. 12, 2024 /PRNewswire/ -- Boan Biotech recently announced that subject enrollment for the international multicenter comparative clinical (Phase 3) study...
2024-01-12 21:15
2421
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients
YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Tra...
2024-01-12 18:17
1692
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference（"JPMHC"）2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...
2024-01-11 16:32
1671
A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence
RALEIGH, N.C., Jan. 10, 2024 /PRNewswire/ -- A new study, "1,5-Anhydroglucitol: A Novel Biomarker of Adherence in Sodium -Glucose Cotransporter 2 Inhibitors," was published online onDecember 13, 2023, in Diabetes Care, a journal from the American Diabetes Association. The study was conducted b...
2024-01-10 20:00
1241
Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing Long-Read Sequencing Applications
SINGAPORE, Jan. 10, 2024 /PRNewswire/ -- Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene's commitment to enhancing...
2024-01-10 10:30
2105
GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing
PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing...
2024-01-09 22:00
1114
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
ROCKVILLE, Md. and SUZHOU, China, Jan. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
2024-01-09 08:00
3374
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform
South Korea's first CAR-NK cell therapy cleared for human trials in Australia
and domestically; Cancer Moonshot participant GC Cell partnering with medical
AI leader Lunit to collaborate on AB-201 clinical development
YONGIN, South Korea and SYDNEY, Jan. 9, 2024 /PRNewswire/ -- GC Cell
2024-01-09 00:00
1402
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...
2024-01-08 20:30
1249
The World's First Clinical Base Editing Therapy for Hemoglobinopathy
CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of
Transfusion-Dependent β-Thalassemia
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 8, 2024, Shanghai,China,
CorrectSequence Therapeutics Co., Ltd.
2024-01-08 19:46
1544
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organ...
2024-01-08 16:00
1257
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...
2024-01-08 15:30
1171
Suvoda Announces 30% Growth in 2023 Driven by Strong Customer Adoption of New Suvoda Platform and Products
Company maintained industry-leading quality metrics throughout growth surge. PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, su...
2024-01-08 08:00
1286
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...
2024-01-05 19:44
2436
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...
2024-01-05 14:35
1573
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...
2024-01-05 00:19
2100
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...
2024-01-04 21:02
1476
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...
2024-01-03 19:37
1414
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...
2024-01-03 18:10
1536
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 326 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 321 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 306 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 276 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
11042
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
9485
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
8967
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
8270
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7515
